Active	Status	Sponsor type	Region	Phase	Filter
10 Active 3 Inactive 13 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes: « July » « 2025 » M T W T F S S 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1 2 3   - « July » « 2025 » M T W T F S S 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1 2 3   Show only changed items Enrollment:

Advanced Filters

5 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Tanaka, Yasuhito
B-Well 2, NCT05630820 / 2022-002268-53: Study of Bepirovirsen in Nucleos(t)Ide Analogue-treated Participants With Chronic Hepatitis B	Active, not recruiting	3	871	Europe, Canada, Japan, US, RoW	Bepirovirsen, Placebo	GlaxoSmithKline, GlaxoSmithKline Research & Development Limited	Chronic Hepatitis B, Hepatitis B, Chronic	11/25	05/26
B-UNITED, NCT06537414: A Study of Sequential Therapy With Daplusiran/Tomligisiran (DAP/TOM) Followed by Bepirovirsen in Participants Living With Chronic Hepatitis B (CHB)	Recruiting	2	280	Europe, Canada, Japan, US, RoW	Daplusiran/Tomligisiran Dose Level 1, Daplusiran/Tomligisiran Dose Level 2, Bepirovirsen, Placebo	GlaxoSmithKline	Chronic Hepatitis B Virus Infection, Hepatitis B	07/27	07/27
B-Sure, NCT04954859 / 2021-000554-26: Long-term Follow-up Study to Evaluate Durability of Treatment Response in Previous Bepirovirsen Study Participants	Recruiting	2	450	Europe, Canada, Japan, US, RoW	Bepirovirsen, Placebo	GlaxoSmithKline, GlaxoSmithKline Research & Development Limited	Hepatitis B	02/29	02/29
Nozawa, Kazuki
PRELUDE, NCT06976944: Pembrolizumab + Paclitaxel +/- Bevacizumab for Triple-negative Breast Cancer	Recruiting	2	44	Japan	Pembrolizumab, Paclitaxel, Bevacizumab	Yukinori Ozaki, Merck Sharp & Dohme LLC	Recurrent Triple-Negative Breast Cancer	09/28	09/28
Kanemitsu, Yoshihiro
RESTORE, NCT06542484: The Real-world Treatment Satisfaction by Gefapixiant in RCC	Recruiting	N/A	63	Japan	Gefapixant Citrate, LYFNUA Tablets	Nagoya City University, Merck Sharp & Dohme LLC	Chronic Cough	03/26	06/26

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Tanaka, Yasuhito
B-Well 2, NCT05630820 / 2022-002268-53: Study of Bepirovirsen in Nucleos(t)Ide Analogue-treated Participants With Chronic Hepatitis B	Active, not recruiting	3	871	Europe, Canada, Japan, US, RoW	Bepirovirsen, Placebo	GlaxoSmithKline, GlaxoSmithKline Research & Development Limited	Chronic Hepatitis B, Hepatitis B, Chronic	11/25	05/26
B-UNITED, NCT06537414: A Study of Sequential Therapy With Daplusiran/Tomligisiran (DAP/TOM) Followed by Bepirovirsen in Participants Living With Chronic Hepatitis B (CHB)	Recruiting	2	280	Europe, Canada, Japan, US, RoW	Daplusiran/Tomligisiran Dose Level 1, Daplusiran/Tomligisiran Dose Level 2, Bepirovirsen, Placebo	GlaxoSmithKline	Chronic Hepatitis B Virus Infection, Hepatitis B	07/27	07/27
B-Sure, NCT04954859 / 2021-000554-26: Long-term Follow-up Study to Evaluate Durability of Treatment Response in Previous Bepirovirsen Study Participants	Recruiting	2	450	Europe, Canada, Japan, US, RoW	Bepirovirsen, Placebo	GlaxoSmithKline, GlaxoSmithKline Research & Development Limited	Hepatitis B	02/29	02/29
Nozawa, Kazuki
PRELUDE, NCT06976944: Pembrolizumab + Paclitaxel +/- Bevacizumab for Triple-negative Breast Cancer	Recruiting	2	44	Japan	Pembrolizumab, Paclitaxel, Bevacizumab	Yukinori Ozaki, Merck Sharp & Dohme LLC	Recurrent Triple-Negative Breast Cancer	09/28	09/28
Kanemitsu, Yoshihiro
RESTORE, NCT06542484: The Real-world Treatment Satisfaction by Gefapixiant in RCC	Recruiting	N/A	63	Japan	Gefapixant Citrate, LYFNUA Tablets	Nagoya City University, Merck Sharp & Dohme LLC	Chronic Cough	03/26	06/26